Population pharmacokinetics of amikacin in patients with pediatric cystic fibrosis.

The regimen of 30  mg-1  kg-1  day-1 every 24 hours more adequately fulfilled the therapeutic target for amikacin. Although all our patients had good clinical results and a good adverse-events profile, further studies are necessary to redefine the optimal treatment strategy.